Clinical Trials Search

Advanced

Trials portfolio

DURANCE
A phase Ib/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive bladder CancEr

DURANCE is a multi-centre, phase Ib/II, single-arm study looking at the safety and activity of combining durvalumab (a checkpoint inhibitor) with S-488210/S-488211 (a novel cancer peptide vaccine) in [...]

Area: Genito-urinary cancer

Phase: Phase I/II

Status: Active (recruiting)

NEPTUNES
Nivolumab and Ipilimumab treatment in prostate cancer with an immunogenic signature

NEPTUNES is a single arm, multicentre phase II study for patients with metastatic prostate adenocarcinoma which has not responded to 1st line treatments with androgen blockage.There are 2 stages.The f [...]

Area: Genito-urinary cancer

Phase: Phase II

Status: In follow-up (non-recruiting)

PARADIGM
Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic prostate cancer

A prospective, observational, biomarker-focused, translational platform, cohort study in newly diagnosed polymetastatic prostate cancer patients starting long-term systemic therapy.

Area: Genito-urinary cancer

Phase: Observational trials

Status: Active (recruiting)

Contact Us

Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map

Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899

CTC staff

University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2024 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us